What is the appropriate management of hiccups in a patient with acute coronary syndrome?

Management of Hiccups in Acute Coronary Syndrome Patients

Hiccups in an ACS patient require immediate recognition as a potential atypical presentation of myocardial ischemia, particularly inferior wall infarction, and should prompt ECG evaluation while simultaneously treating the underlying coronary pathology as the primary intervention.

Recognition and Diagnostic Approach

• Hiccups can be an atypical presenting symptom of myocardial ischemia/infarction, with inferior myocardial infarction being the most common cardiac cause 1, 2.
• The mechanism involves irritation of the phrenic nerve from infarcted myocardium, activating the hiccup reflex arc 2.
• In elderly patients or those with cardiac risk factors presenting with persistent hiccups of uncertain cause, obtain an ECG immediately to identify cardiogenic etiology 1.
• Hiccups associated with ACS have been reported in patients with severe triple vessel disease, not just isolated inferior wall involvement 2.

Primary Management: Treat the Underlying ACS

The most effective management is directed at the underlying coronary pathology 3:

• Initiate standard ACS therapy immediately: aspirin loading dose (162-325 mg) followed by dual antiplatelet therapy with ticagrelor or prasugrel preferred over clopidogrel 4.
• Provide anti-ischemic therapy: nitroglycerin (sublingual 0.3-0.4 mg every 5 minutes up to 3 doses, or IV starting at 10 μg/min) for hemodynamically stable patients with SBP ≥90 mmHg 5.
• Proceed with coronary angiography and revascularization (PCI or CABG) as indicated by ACS guidelines 4, 1.
• Hiccups often resolve after successful revascularization, whether by PCI or coronary artery bypass grafting 1, 2.

Important Caveat on Opioid Use

• While morphine (2-4 mg IV) or fentanyl (25-50 μg IV) may be used for refractory chest pain 5, be aware that opioids may delay gastric absorption of oral P2Y12 inhibitors, potentially delaying their pharmacodynamic effects 5.
• Opioids should not be used solely to mask ischemic symptoms 5.

Symptomatic Treatment of Persistent Hiccups

If hiccups persist despite treating the underlying ischemia, consider pharmacological intervention:

First-Line Agents

• Baclofen is the preferred first-line agent based on randomized controlled trial data, with gabapentin as an alternative 3.
• Baclofen was specifically effective in one ACS case with persistent hiccups 6.
• These agents have fewer side effects during long-term therapy compared to neuroleptic agents 3.

Second-Line Agents

• Metoclopramide has support from small randomized placebo-controlled trials 3.
• Chlorpromazine has observational data supporting efficacy but carries more adverse effects, particularly problematic in stroke rehabilitation or palliative care settings 1, 3.

Alternative Therapy

• Acupuncture at acupoint GV14 (Da zhui) rapidly terminated intractable hiccups in one reported case of acute MI when conventional therapies (including metoclopramide, chlorpromazine, haloperidol, baclofen, and others) failed for 7 days 7.
• This may be considered for refractory cases 7.

Clinical Pitfalls to Avoid

• Do not dismiss persistent hiccups as benign in patients with cardiac risk factors or known coronary disease—they may indicate active ischemia 1, 2.
• Do not delay ECG and cardiac biomarkers while attempting symptomatic hiccup treatments 1.
• Avoid NSAIDs for any pain management in ACS patients, as they increase risk of major adverse cardiovascular events 5.
• Do not use nitrates if the patient has taken phosphodiesterase-5 inhibitors (within 12h of avanafil, 24h of sildenafil/vardenafil, or 48h of tadalafil) 5.

Risk Stratification Context

Consider that hiccups with ACS may occur in high-risk populations:

• Elderly patients with multiple cardiovascular risk factors 1, 2
• Patients with diabetes, hypertension, and prior ischemic events 2
• Dialysis patients where hiccups may signal both myocardial injury and potential CNS involvement 6